We propose that, after surgical removal of the primary melanoma lesion, the amoeboid phenotype should be targeted using either ROCKi or IL-1α blocking antibodies as therapies to restrict immunosuppressive microenvironments and metastatic dissemination. Here, IL1A is linked to melanoma.